Pedmark® (sodium thiosulfate injection)

About Fennec Pharmaceuticals

Fennec Pharmaceuticals is a specialized biotech with a singular mission: to protect the hearing of cancer survivors treated with cisplatin chemotherapy. The company successfully launched Pedmark®, its first commercial product, following FDA approval in 2022. Its current strategy involves driving commercial adoption in pediatrics, pursuing label expansion into adult head & neck and testicular cancers through investigator-sponsored trials, and defending its intellectual property. Fennec represents a focused play on oncology supportive care with a significant unmet medical need.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals is a specialized biotech with a singular mission: to protect the hearing of cancer survivors treated with cisplatin chemotherapy. The company successfully launched Pedmark®, its first commercial product, following FDA approval in 2022. Its current strategy involves driving commercial adoption in pediatrics, pursuing label expansion into adult head & neck and testicular cancers through investigator-sponsored trials, and defending its intellectual property. Fennec represents a focused play on oncology supportive care with a significant unmet medical need.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals is a specialized biotech with a singular mission: to protect the hearing of cancer survivors treated with cisplatin chemotherapy. The company successfully launched Pedmark®, its first commercial product, following FDA approval in 2022. Its current strategy involves driving commercial adoption in pediatrics, pursuing label expansion into adult head & neck and testicular cancers through investigator-sponsored trials, and defending its intellectual property. Fennec represents a focused play on oncology supportive care with a significant unmet medical need.

Therapeutic Areas